CAS No. |
2158322-29-1 |
中文名称 |
(S)-1-(((3S,4S)-7-氰基-5-(4-((2-(2-(2-((2-(4-((E)-1-(4-羟基苯基)-2-苯基丁-1-烯-1-基)苯氧基)乙基)(甲基)氨基)-2-氧代乙氧基)乙氧基)乙基)氨基甲酰基)苯甲酰基)-1-((2-甲氧基萘-1-基)甲基)-4-甲基-2-氧代-2,3,4,5-四氢-1H-苯并[e][1,4]二氮杂卓-3-基)氨基)-1-氧代丙-2-基)氨基甲酸叔丁酯 |
英文名称 |
tert-Butyl ((S)-1-(((3S,4S)-7-cyano-5-(4-((2-(2-(2-((2-(4-((E)-1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)(methyl)amino)-2-oxoethoxy)ethoxy)ethyl)carbamoyl)benzoyl)-1-((2-methoxynaphthalen-1-yl)methyl)-4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-ben |
别名 |
PROTAC ER Degrader-3;Carbamic acid, N-[(1S)-2-[[(3S,4S)-7-cyano-2,3,4,5-tetrahydro-5-[4-[[[2-[2-[2-[[2-[4-[1-(4-hydroxyphenyl)-2-phenyl-1-buten-1-yl]phenoxy]ethyl]methylamino]-2-oxoethoxy]ethoxy]ethyl]amino]carbonyl]benzoyl]-1-[(2-methoxy-1-naphthalenyl)methyl]-4-methyl-2-oxo-1H-1,5-benzodiazepin-3-yl]amino]-1-methyl-2-...;Carbamic acid, N-[(1S)-2-[[(3S,4S)-7-cyano-2,3,4,5-tetrahydro-5-[4-[[[2-[2-[2-[[2-[4-[1-(4-hydroxyphenyl)-2-phenyl-1-buten-1-yl]phenoxy]ethyl]methylamino]-2-oxoethoxy]ethoxy]ethyl]amino]carbonyl]benzoyl]-1-[(2-methoxy-1-naphthalenyl)methyl]-4-methyl-2-oxo-1H-1,5-benzodiazepin-3-yl]amino]-1-methyl-2-oxoethyl]-N-methyl-, 1,1-dimethylethyl ester |
标准英文名 |
tert-butyl ((S)-1-(((3S,4S)-7-cyano-5-(4-((2-(2-(2-((2-(4-((E)-1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)(methyl)amino)-2-oxoethoxy)ethoxy)ethyl)carbamoyl)benzoyl)-1-((2-methoxynaphthalen-1-yl)methyl)-4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate |
分子式 |
C71H77N7O12 |
分子量 |
1220.43
|
精确分子量 |
1219.56
|
SMILES |
COC(C=CC1=C2C=CC=C1)=C2CN3C([C@@H](NC([C@@H](N(C(OC(C)(C)C)=O)C)C)=O)[C@H](C)N(C(C4=CC=C(C(NCCOCCOCC(N(CCOC5=CC=C(/C(C6=CC=C(O)C=C6)=C(CC)/C7=CC=CC=C7)C=C5)C)=O)=O)C=C4)=O)C8=CC(C#N)=CC=C83)=O |
标准SMILES |
COC1C=CC2C=CC=CC=2C=1CN1C2=CC=C(C=C2N([C@@H](C)[C@H](NC(=O)[C@H](C)N(C)C(=O)OC(C)(C)C)C1=O)C(=O)C1C=CC(=CC=1)C(=O)NCCOCCOCC(=O)N(C)CCOC1C=CC(=CC=1)/C(=C(\CC)/C1C=CC=CC=1)/C1C=CC(O)=CC=1)C#N |
用途 |
PROTAC ER Degrader-3 is an intermediate used in the synthesis of PAC (PROTAC-Antibody Conjugate), which consists of an ADC linker and a PROTAC molecule conjugated to an antibody. When conjugated to an antibody, PAC demonstrates significantly enhanced degradation of estrogen receptor alpha (ERα) compared to non-conjugated PROTAC. |
InChIKey |
ZBSUUCSLUPVKFV-HQXVZGQMSA-N |